XBiotech's 'True Human' Antibody Xilonix Hits the Spot for Cachexia
Austin-based XBiotech Inc. is launching its first Phase III trial, for its antibody Xilonix (MABp1), after announcing Wednesday that the monoclonal antibody received fast-track designation by the FDA.
Xilonix will be tested for the treatment of cachexia, a wasting syndrome that can occur with cancer as well as other chronic diseases. In the Phase II trial that was the basis of the fast-track designation, about a third of patients responded to the antibody. And those that did not only started building muscle, but had increased survival as well.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter